Q1 2018 13F Holders as of 31 Mar 2018
-
Type / Class
-
Equity / SHS
-
Total 13F shares
-
25,291,213
-
Share change
-
+2,773,032
-
Total reported value
-
$127,212,030
-
Put/Call ratio
-
169%
-
Price per share
-
$5.03
-
Number of holders
-
45
-
Value change
-
+$13,609,043
-
Number of buys
-
16
-
Number of sells
-
22
Institutional Holders of NABRIVA THERAPEUTICS PLC - SHS as of Q1 2018
As of 31 Mar 2018,
NABRIVA THERAPEUTICS PLC - SHS was held by
45 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
25,291,213 shares.
The largest 10 holders included
WELLINGTON MANAGEMENT GROUP LLP, Vivo Capital, LLC, ORBIMED ADVISORS LLC, Novo Holdings A/S, venBio Partners L.P., BAKER BROS. ADVISORS LP, MILLENNIUM MANAGEMENT LLC, Hillhouse Capital Management, Ltd., Alyeska Investment Group, L.P., and Rock Springs Capital Management LP.
This page lists
45
institutional shareholders reporting positions in this security
for the Q1 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.